jRCT ロゴ

臨床研究等提出・公開システム

Top

Japanese

June. 13, 2024

June. 13, 2024

jRCT2033240156

Follow-up study of human induced Pluripotent Stem (iPS) cell-derived cardiomyocyte spheroids in patients with severe heart failure, secondary to ischemic heart disease, undergoing coronary artery bypass grafting

Follow-up study of human induced Pluripotent Stem (iPS) cell-derived cardiomyocyte spheroids in patients with severe heart failure, secondary to ischemic heart disease, undergoing coronary artery bypass grafting

Kaneko Takehiko

Heartseed Inc

1-2-3, Shibaura, Minato-ku Tokyo

+81-3-6380-1068

chiken@heartseed.jp

Toiawase Madoguchi

Heartseed Inc

1-2-3, Shibaura, Minato-ku Tokyo

+81-3-6380-1068

chiken@heartseed.jp

Recruiting

June. 13, 2024

10

Interventional

single arm study

open(masking not used)

uncontrolled control

single assignment

treatment purpose

Subjects who participated in the HS-001-01 study and were transplanted with HS-001CS and who were able to obtain voluntary consent in writing for inclusion in this clinical trial.

Patients judged by the Investigator to be ineligible shall not be included in the Clinical Trial.

20age old over
80age old under

Both

Heart failure with ischemic heart disease

To take immunosuppressant tacrolimus or other immunosuppressant

Ischemic heart disease, Heart Failure, Coronary artery bypass grafting (CABG)

Safety

Safety

Heartseed Inc
Tokyo Womens Medical University Institutional Review Board
8-1,Kawada-cho,Shinjuku-ku,Tokyo,Japan, Tokyo

+81-3-3353-8111

Approval

No

none